Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.42 |
| ▸ | NPC1 | O15118 | 7/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10120992 | 0.88 | S1PR1 (0.45) | RAB9AS1PR1S1PR3ALDH1A1NPC1 | |
| SCHEMBL9208436 | 0.85 | RAB9A (0.38) | RAB9AS1PR1S1PR3ALDH1A1NPC1 | |
| SCHEMBL19364783 | 0.85 | RAB9A (0.42) | RAB9AS1PR1S1PR3ALDH1A1NPC1 | |
| SCHEMBL11928813 | 0.84 | RAB9A (0.39) | RAB9AS1PR1S1PR3ALDH1A1NPC1 | |
| SCHEMBL854822 | 0.82 | S1PR1 (0.42) | RAB9AS1PR1S1PR3ALDH1A1NPC1 | |
| SCHEMBL9285410 | 0.81 | — | — | |
| SCHEMBL21350422 | 0.79 | S1PR1 (0.40) | RAB9AS1PR1S1PR3ALDH1A1NPC1 | |
| SCHEMBL20427474 | 0.77 | RAB9A (0.49) | RAB9AS1PR1S1PR3ALDH1A1NPC1 | |
| SCHEMBL12436967 | 0.77 | RAB9A (0.36) | RAB9ANPC1EPHX2HPGD | |
| SCHEMBL9629469 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208923-A1 | SMALL MOLECULE INHIBITORS OF MAMMALIAN SLC6A19 FUNCTION | JNANA THERAPEUTICS INC. | 2024-06-27 | — | — | US | disclosed |
| US-10752611-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-10550149-B2 | PPAR agonists and methods of use thereof | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2020-02-04 | — | — | US | disclosed |
| US-9765087-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-8101643-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20100233122-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100233122-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | RAB9A 3679/4885S1PR1 3018/4885S1PR3 2747/4885 |
| US-20240208923-A1 | SMALL MOLECULE INHIBITORS OF MAMMALIAN SLC6A19 FUNCTION | SLC18A2, SLC6A19, SLC1A1 | RAB9A 227/4885S1PR1 3912/4885S1PR3 4034/4885 |
| US-10550149-B2 | PPAR agonists and methods of use thereof | PPARD, PPARG, PPARA | RAB9A 2824/4885S1PR1 1579/4885S1PR3 1474/4885 |
| US-10752611-B2 | Benzimidazole derivatives | EIF2AK2, ZC3HAV1, ZC3HAV1L | RAB9A 3990/4885S1PR1 2523/4885S1PR3 2406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.